The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 59-65

  He, Kuifeng ^a   Cui, Binbin ^b   Li, Guangliang ^a   Wang, Haohao ^a   Jin, Ketao ^a   Teng, Lisong ^a  

^a First Affiliated Hospital   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Antiangiogenic; Chemotherapy; Tumors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; TRASTUZUMAB;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; NONHUMAN; PROTEINURIA; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84861369217     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S29719     Document Type: Review

References (63)

1. Ortega J, Vigil CE, Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. Cancer Control. 2010;17(1):7-15.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
4. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc). 2008;73(7):751-762.
5. Döme B, Hendrix MJ, Paku S, Tóvári J, Tímár J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol. 2007;170(1):1-15.
6. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg. 2007;42(1):1-11.
7. Van Cutsem E, Tabernero J, Lakomy R, et al. ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients. Annals of Oncology. 2011;22(Suppl 5):v18.
8. Folkman J. Clinical Applications of Research on Angiogenesis. N Engl J Med. 1995;333(26):1757-1763.
9. Zetter BR. Angiogenesis and tumor metastasis. Annu Rev Med. 1998;49:407-424.
10. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3(6):401-410.
11. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-1027.
12. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004; 9 Suppl 1: 2-10.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-1027.
14. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400.
15. Carrato A, Gallego-Plazas J, Guillen-Ponce C. Anti-VEGF therapy: a new approach to colorectal cancer therapy. Expert Rev Anticancer Ther. 2006;6(10):1385-1396.
16. Ishigami SI, Arii S, Furutani M, et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer. 1998;78(10):1379-1384.
17. Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer. 1999;81(6): 845-850.
18. Martins SF, Reis RM, Rodrigues AM, Baltazar F, Filho AL. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol. 2011;2(6): 272-280.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
20. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006;312(5777):1171-1175.
21. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapyinduced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008;14(3):263-273.
22. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843-850.
23. Scheithauer W, Schmiegel W. Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer. Onkologie. 2009; 32(7):431-439.
24. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007;25(30):4779-4786.
25. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26(4):689-690.
26. Cassidy J, Clarke S, Diaz-Rubio E, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer. June 28, 2011;105(1):58-64.
27. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539-1544.
28. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005;23(16):3706-3712.
29. Hurwitz H, Kabbinavar F. Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology. 2005;69 Suppl 3:17-24.
30. Chu E. An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2012; 11(1):1-13.
31. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14(9): 862-870.
32. Samelis GF, Ekmektzoglou KA, Tsiakou A, Konstadoulakis M. The Continuation of Bevacizumab Following Disease Progression in Patients with Metastatic Colorectal Cancer Offers a Survival Benefit. Hepatogastroenterology. 2011;58(112):1968-1971.
33. Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer. 2001;85(4):584-589.
34. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004;18(5):1007-1021.
35. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672-680.
36. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360(6):563-572.
37. Saltz L, Badarinath S, Dakhil S, et al. Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs FOLFOX-Bevacizumab in Colorectal Cancer. Clin Colorectal Cancer. 2011. [Epub ahead of print.]
38. De Gramont A, Van Cutsem E, Tabernero J, et al. AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. ASCO Meeting Abstracts. February 3, 2011;29(Suppl 4):362.
39. Wolmark N, Yothers G, O'Connell MJ, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. ASCO Meeting Abstracts. June 8, 2009;27(15S):A4.
40. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398.
41. Stewart MW. Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug. Inflamm Allergy Drug Targets. 2011;10(6):497-508.
42. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest. 2004;113(7): 1040-1050.
43. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A. 2002;99(17):11399-11404.
44. Teng LS, Jin KT, He KF, Zhang J, Wang HH, Cao J. Clinical applications of VEGF-trap (aflibercept) in cancer treatment. J Chin Med Assoc. 2010;73(9):449-456.
45. Lal D, Park JA, Demock K, et al. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Mol Cancer Ther. 2010;9(10):2737-2751.
46. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Vascular endothelial growth factor trap combined with paclitaxel trikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res. 2005;11(19 Pt 1): 6966-6971.
47. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28(2):207-214.
48. Tew WP, Gordon M, Murren J, et al. Phase 1study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res. 2010;16(1):358-366.
49. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19):2689-2695.
50. Jin K, Shen Y, He K, Xu Z, Li G, Teng L. Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol. 2010;12(8):526-532.
51. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A. 2007;104(47):18363-18370.
52. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011;3(1):76-99.
53. Regeneron Pharmaceuticals Inc. Press Release Reporting Two Year Results of Phase 3 Studies with ELYEA™ (aflibercept) Injection in wet AMD Show Sustained Improvement in Visual Acuity [press release]. Tarrytown, NY: Regeneron; December 5, 2000.
54. Sanofi-Aventis; Regenreron Pharmaceuticals. Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). June 15, 2009 [last updated on November 2, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00921661. NLM Identifier: NCT00921661.
55. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26(33):5326-5334.
56. Mass RD, Sarkar S, Holden SN, Hurwitz H. Clinical benefit from bevacizumab (BV) in responding (R) and non-responding (NR) patients (pts) with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts. May 28, 2005;23(Suppl 16):3514.
57. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(3):453-459.
58. Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR). Combination Chemotherapy and Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). December 14, 2005 [last updated February 6, 2009]. Avaialble from: http://clinicaltrials.gov/ct/show/NCT00265824. NLM identifier: NCT00265824.
59. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs. 2006;7(6):522-528.
60. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4(6):423-436.
61. Pohl M, Werner N, Munding J, et al. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature. Z Gastroenterol. 2011;49(10):1398-1406.
62. Loupakis F, Bocci G, Pasqualetti G, et al. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. Curr Cancer Drug Targets. 2010;10(1): 37-45.
63. Matsusaka S, Suenaga M, Mishima Y, et al. Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2011;68(3):763-768.